Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.

Takami, Akiyoshi

Takami, Akiyoshi.

Takami A; Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan. takami-knz@umin.ac.jp.

Int J Hematol ; 112(1): 122-124, 2020 Jul.

Article in English | MEDLINE | ID: covidwho-245070

Subject(s)

Coronavirus Infections/drug therapy; Etoposide/therapeutic use; Lymphohistiocytosis, Hemophagocytic/drug therapy; Pneumonia, Viral/drug therapy; Topoisomerase II Inhibitors/therapeutic use; Betacoronavirus/drug effects; Betacoronavirus/immunology; COVID-19; Coronavirus Infections/complications; Coronavirus Infections/immunology; Cytokines/immunology; Dose-Response Relationship, Drug; Etoposide/administration & dosage; Humans; Lymphohistiocytosis, Hemophagocytic/complications; Lymphohistiocytosis, Hemophagocytic/immunology; Macrophages/drug effects; Macrophages/immunology; Pandemics; Pneumonia, Viral/complications; Pneumonia, Viral/immunology; SARS-CoV-2; Topoisomerase II Inhibitors/administration & dosage

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Lymphohistiocytosis, Hemophagocytic / Etoposide / Topoisomerase II Inhibitors Topics: Long Covid Limits: Humans Language: English Journal: Int J Hematol Journal subject: Hematology Year: 2020 Document Type: Article Affiliation country: S12185-020-02888-9

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google